SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-052326
Filing Date
2021-02-23
Accepted
2021-02-23 16:06:07
Documents
12
Period of Report
2021-02-17
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d120087d8k.htm   iXBRL 8-K 22832
  Complete submission text file 0001193125-21-052326.txt   144720

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA pbyi-20210217.xsd EX-101.SCH 3096
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE pbyi-20210217_lab.xml EX-101.LAB 18138
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pbyi-20210217_pre.xml EX-101.PRE 11425
5 EXTRACTED XBRL INSTANCE DOCUMENT d120087d8k_htm.xml XML 3369
Mailing Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024
Business Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024 (424) 248-6500
PUMA BIOTECHNOLOGY, INC. (Filer) CIK: 0001401667 (see all company filings)

IRS No.: 770683487 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35703 | Film No.: 21665392
SIC: 2834 Pharmaceutical Preparations